Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Distinct Trajectories of Patient-reported Outcome Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy: A Prospective Longitudinal Study
Yanhong Zhou; Xiaomeng Lu; Wenhui Geng; Fengxia Liu; Lei Li; Jiahui LiuShow moreShow less
Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; Department of Nursing, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaShow moreShow less
Acute Radiation Dermatitis and Recovery After Ultra-hypofractionated Versus Hypofractionated Whole-breast Radiation Therapy: A Retrospective Cohort Study
Samantha Juang; Julia Neiswander; Ashwin Ragupathi; Jasky Karem; Rosario Campo; Xueqing Huang; Dong Zhang; Maria Plummer; Rajasree Roy; Edward ObedianShow moreShow less
Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; Department of Computer Sciences, College of Engineering and Computing Sciences, New York Institute of Technology, Old Westbury, NY; Center for Cancer Research, New York Institute of Technology, Old Westbury, NY; Department of Clinical Specialties, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; St. Francis Hospital and Heart Center, The Cancer Institute, East Hills, NYShow moreShow less
Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET/CT in Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Seyma Erdogan; Yusufcan Yılmaz; Elif Reyhan Aslan; Refia Yukselturk; Efnan Algın; Berna Okudan; Osman Inan; Oznur BalShow moreShow less
Department of Internal Medicine, Health Science University, Ankara City Hospital, Ankara, Turkey; Department of Nuclear Medicine, Health Science University, Ankara City Hospital, Ankara, Turkey; Department of Medical Oncology, Health Science University, Ankara City Hospital, Ankara, TurkeyShow moreShow less
Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
Hannah M. Linden; Sophia R. O’Brien; Stephanie M. van de Ven; Paul La Porte; Peter S. Conti; Parvin F. Peddi; Joanne E. Mortimer; Christiana Brenin; Amol M. Takalkar; Julia E. McGuinness; Edgar Cheng; Amol Rao; Lanell M. Peterson; Jennifer M. Specht; Terence Z. Wong; David A. Buck; Adam M. Brufsky; Gary A. UlanerShow moreShow less
Department of Medicine, Division of Hematology/Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA; GE HealthCare, Pharmaceutical Diagnostics Research and Development, San Diego, CA; Medical Oncology, The Oncology Institute, CA; Department of Radiology, Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, CA; Margie Petersen Breast Center, Providence Saint John’s Cancer Institute, Santa Monica, CA; Department of Medical Oncology, City of Hope, Duarte, CA; Division of Hematology/Oncology, University of Virginia, Charlottesville, VA; Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA; Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, NY; Nuclear Medicine, St. Luke's University Health Network, Bethlehem, PA; Hematology-Oncology, MemorialCare Cancer Institute, Fountain Valley, CA; Division of Nuclear Medicine and Radiotheranostics, Department of Radiology, Duke Health, Durham, NC; Radiation Oncology, Blue Ridge Cancer Care, Roanoke, VA; Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California and Departments of Radiology and Cancer Biology, University of Southern California, Los Angeles, CAShow moreShow less
Incidence and Treatment Patterns of Pleomorphic Lobular Carcinoma in Situ: A Population-based Analysis After the Introduction of ICD-O-3 Code 8519/2
İsmail Zihni; Mehmet Zafer SabuncuoğluShow moreShow less
Department of General Surgery, Faculty of Medicine, Akdeniz University, Antalya, TürkiyeShow moreShow less
The Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer Among Patients Diagnosed With Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Core Needle Biopsy
Komal Ijaz; Broden Alston; Therese Bevers; Banu Arun; Diane Weber; Min Yi; Kelly Hunt; Gary Whitman; Lavinia P. MiddletonShow moreShow less
Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TXShow moreShow less
FAQ
How long does Clinical Breast Cancer take to review a manuscript?
As of 2026-11-14, CrushSCI has 15 complete review records for Clinical Breast Cancer. The fastest paper went from submission to acceptance in 4 days (Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study, received 2026-08-06, accepted 2026-08-10); the slowest took 296 days. The average is 87.3 days and the median is 79 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
